Henry Schein, Inc., headquartered in Melville, N.Y., is a leading provider of healthcare products and services to office-based dental and medical practitioners. Founded by Henry Schein and Esther Schein in 1932, the company is now led by Stanley M. Bergman and has more than 19,000 employees worldwide. It serves more than one million customers globally.
Henry Schein’s operations are organized into two principal segments: healthcare distribution and technology. The healthcare distribution segment distributes consumables products, lab products, services, equipment, vaccines, pharmaceuticals, and surgical products. The technology segment provides software, technology, and other value-added services to its healthcare practitioners.
The company has a well-established reputation for being customer-centric. Henry Schein’s operations are guided by the belief in "doing well by doing good." It aids its customers to operate efficient practices while delivering high-quality care by providing a broad array of solutions, delivered by committed team Schein members.
What sets Henry Schein apart is its strong supply chain network, which spans North America, Europe, and the Asia-Pacific region. The company’s strong global footprint empowers it to reach more customers and tap into new markets. Its extensive product portfolio covers both generic and specialty drugs.
Henry Schein is also deeply invested in the communities it serves. Through its Henry Schein Cares program, the company funds various charitable initiatives globally that focus on increasing access to healthcare for underserved populations.
Furthermore, the company’s commitment towards sustainability is evident from its participation in eco-conscious initiatives. Henry Schein, Inc. is keen on promoting resource efficiency in its operations and reducing its carbon footprint with programs like the Henry Schein Green initiative.
The company operates under high standards of corporate governance and social responsibility, dedicating considerable resources to ethics and compliance programs. Henry Schein, Inc. is not only dedicated to its mission of delivering the best health to healthcare professionals—they go a step further to ensure the well-being and progress of communities surrounding their fields of operation.
Despite the challenges posed by the volatile economic environment, Henry Schein continues to show steady growth both organically and through strategic acquisitions. Its stock is listed on the NASDAQ Stock Market under the symbol "HSIC". Notably, it was also named as a Fortune World’s Most Admired Company for three consecutive years, from 2016-2018, a testament to its reliable business model and management caliber.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Henry Schein Inc. (NASDAQ: HSIC) reported third-quarter earnings that surpassed estimates, with sales nearly in line with consensus. Despite strong U.S. dental merchandise sales and stable overall market conditions, the company faces pressure from delays in discretionary dental procedures due to patients being sensitive to out-of-pocket costs. Henry Schein raised its fiscal 2026 adjusted earnings guidance but reaffirmed its sales outlook.
Henry Schein (NASDAQ: HSIC) announced strong third-quarter 2026 financial results, including an 8.6% increase in U.S. dental merchandise sales and a 19.1% rise in adjusted non-GAAP diluted EPS. The company also expanded non-GAAP operating margins and repurchased $125 million in stock, raising its full-year 2026 financial guidance. Management expressed confidence in achieving double-digit earnings growth in 2027, driven by strategic initiatives focused on growth acceleration, operational simplification, and enhanced execution discipline.
Henry Schein Inc. (HSIC) reported strong third-quarter results, with net income of $119 million and adjusted earnings of $1.56 per share, surpassing analyst expectations. The health care products maker achieved revenue of $3.47 billion, matching Street forecasts, and provided a full-year earnings outlook.
McKesson (NYSE: MCK), a healthcare distributor and services company, is set to report its Q3 earnings this Wednesday after market close. The market expects a 6.7% year-on-year revenue growth, a slowdown from the 10.1% increase in the same quarter last year, despite the company beating revenue expectations last quarter. Investors will be watching closely as analyst estimates have remained largely consistent, suggesting a steady performance is anticipated.
Shares of Henry Schein Inc. (HSIC) fell 1.80% on Friday to $84.88, despite the stock outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines during the trading session. This marks the end of a two-day winning streak for the stock.
Staar Surgical (STAA) is projected to experience a year-over-year decline in both earnings and revenues for the quarter ending September 2026, with an expected EPS of $0.19, down 58.7%, and revenues of $81.53 million, a 13.9% decrease. Despite a 20% upward revision in the consensus EPS estimate over the last 30 days, the company's Zacks Earnings ESP of -12.07% combined with a Zacks Rank #1 makes it difficult to definitively predict an earnings beat. Investors should monitor the actual results, expected on November 4, as they could significantly impact the stock's near-term performance.